Driscoll Rimma, an Executive Vice President, has filed 37 Form 4 transactions across just two companies, but the pattern is almost entirely mechanical rather than discretionary. Across all filings, there were zero open-market purchases (code P) and zero open-market sales (code S). The overwhelming majority of activity consists of grants and awards (code A), option exercises (code M), and shares withheld to cover tax obligations (code F). The total value of acquired shares came to $87,260.11, with no corresponding buy or sell dollar value, indicating that every transaction was part of compensation or equity administration rather than a directional bet on the stock.
The recent filings, all dated between February 2024 and July 2026, cluster around Zoetis (ZTS) and DexCom (DXCM). On ZTS, Rimma received recurring restricted stock grants—$6,000 on January 9, 2026, $7,000 on October 10, 2025, and $6,000 on July 11, 2025—alongside larger awards on March 27, 2026, totaling $49,029.24. Those grants were paired with option exercises (code M) and tax-withholding sales (code F) on February 6, 8, and 19, 2026, with the F-transactions valued at $11,340.38, $9,811.34, and $22,783.12 respectively. The DXCM filings were limited to two zero-value grants on May 8, 2025, and May 28, 2026, with no subsequent exercises or sales.
The direction is unambiguous: Rimma is accumulating equity through compensation, not expressing conviction through the market. The absence of any P or S codes across 37 filings means there is no signal of insider optimism or pessimism. The F-transactions are automatic deductions to cover taxes on vested options, and the M-transactions are mechanical conversions of options into shares. The only notable dollar figures—the $49,029.24 in March 2026 ZTS awards—are compensation events, not trades. For investors tracking insider behavior, this filing history offers no directional insight; it is a clean record of an executive being paid in stock and options.
AI-assisted summary